Tag Archives: manufacturing

Jensen Huang says that ‘without TSMC, there is no NVIDIA’

Posted on by
Reply

It’s safe to say that much of the world’s semiconductors run on designs built by Taiwan Semiconductor Manufacturing Company (TSMC). At the last estimate, the company accounted for about 64 percent of the world’s contract chip manufacturing. These designs are also powering many of the AI technology breakthroughs being developed by NVIDIA.

With that in mind, it might come as little surprise that Jensen Huang, NVIDIA’s CEO, had nothing but praise for TSMC during its recent Sports Day event. In fact, Huang went as far as to say that NVIDIA wouldn’t exist without TSMC.

Huang made these comments during TSMC’s Sports Day, as reported by the online news outlet Focus Taiwan. The event took place last weekend at a stadium in Taiwan, where Huang highlighted TSMC’s crucial role in NVIDIA’s history and its broader impact on technology.

He stated, “Without TSMC, there is no Nvidia today. You are really the pride of Taiwan, you are also the pride of the world. Thank you for helping me build Nvidia.”

NVIDIA and TSMC have been collaborating for nearly 30 years. NVIDIA has consistently utilized the technological breakthroughs developed by TSMC in its products, including the company’s cutting-edge Blackwell AI chips.

With such a long history and shared success, Huang clearly has a strong interest in maintaining friendly relations with TSMC. This is especially important as TSMC and the Taiwan region navigate complex trade and export tensions with the United States government.

In summary, the partnership between NVIDIA and TSMC remains a cornerstone of technological innovation, driving advancements in AI and semiconductor manufacturing worldwide.
https://www.shacknews.com/article/146757/jensen-huang-tsmc-pride-of-the-world

Is the Bitcoin price heading for its worst Q4 since 2022?

Posted on by
Reply

**Can Bitcoin Price Recover Its Momentum After October’s Reversal, or Will Q4 Extend Its Weakest Run Since 2022?**

—

### Bitcoin Price Breaks the Uptober Streak

Bitcoin entered October with confidence, extending a powerful rally that lifted prices to a record high above $126,000 on October 6. However, what followed was a sharp and sudden pullback. Within days, prices dropped more than 17%, reaching about $104,500 between October 10 and 11. The month closed with Bitcoin (BTC) down roughly 3.6%, marking its first negative October since 2018.

As of November 3, Bitcoin trades near $108,000, around 14.5% below its monthly peak.

The decline stemmed from several interconnected global developments:

– The U.S.-China trade confrontation intensified after Washington imposed 100% tariffs and introduced new restrictions on software exports. This move sparked heavy liquidations across crypto markets and dampened investor risk appetite.
– At the same time, the Federal Reserve signaled that it may slow the pace of interest rate cuts. This stance strengthened the dollar and increased the appeal of yield-bearing assets, putting additional pressure on Bitcoin, which produces neither interest nor dividends.

Another key factor is Bitcoin’s deeper integration with traditional finance. In past cycles, Bitcoin often moved independently of global markets. Today, institutional trading, ETF flows, and broader macro sentiment shape its direction far more than retail activity alone.

As a result, 2025 broke the “Uptober” streak. Bitcoin is down nearly 6% in Q4 so far, turning what is usually a positive month for crypto into its weakest start since 2022.

The question now is: what lies ahead as the market moves deeper into November and the rest of Q4?

—

### Trade Truce Meets Tight Liquidity

Early November brought what appeared to be relief for global markets.

During a summit in South Korea, U.S. President Joe Biden and Chinese President Xi Jinping reached a broad trade-truce framework that marks a partial de-escalation of the trade war that had intensified earlier this year.

Key points of the agreement include:

– China will begin lifting its export ban on automotive computer chips, including components critical to car production worldwide, addressing a major bottleneck that had disrupted global manufacturing chains.
– The two sides agreed on U.S. soybean exports, with China committing to purchase 12 million metric tons this season and 25 million tons annually for the next three years.
– Cooperation will also involve the supply of rare earth minerals and precursor materials used in the production of the drug fentanyl.
– The U.S. reduced tariffs on Chinese goods from 57% to 47%, while China agreed to delay export restrictions on rare earths, gallium, and germanium for one year.

Despite the political optics of progress, China’s manufacturing sector continues to struggle. The country’s October manufacturing PMI stood at 49, extending its contraction streak to seven months and pointing to lingering weaknesses in global demand and production.

In the U.S., the Federal Reserve moved slightly toward monetary easing, cutting its benchmark rate by 25 basis points to a 3.75-4.00% range at its October 28-29 meeting. This decision came as unemployment inched up from 4.0% to 4.3%, while inflation remained around 3% year on year.

Fed Chair Jerome Powell reiterated that future policy remains data dependent, and markets now expect a 70% chance of a further rate cut in December.

A parallel move came from the U.S. central bank’s liquidity operations. On October 31, the Federal Reserve injected $29.4 billion through overnight repo operations — its largest since 2020.

For Bitcoin and the broader crypto markets, greater liquidity, reduced tariffs, and easing trade tensions theoretically create a supportive backdrop. However, real recovery depends on whether supply chains and credit conditions stabilize enough to renew investor confidence.

—

### The Verdict That Could Shake Bitcoin

The next major test for global markets, and indirectly for Bitcoin, is set to unfold at the U.S. Supreme Court.

On November 5, the Trump administration will face challenges from small businesses and several U.S. states over the legality of tariffs imposed earlier this year under the 1977 International Emergency Economic Powers Act.

The plaintiffs argue that the president exceeded his constitutional authority since the law allows regulation of trade during emergencies but does not explicitly authorize tariffs.

The court’s decision is expected sometime between March and June 2026.

The case involves roughly $90 billion in import taxes already collected through September 2025, according to Wells Fargo estimates. However, administration officials warn that this figure could swell to as much as $1 trillion if the court takes until June 2026 to decide and tariffs remain in place throughout that period.

**Potential outcomes:**

– Should the court rule against the administration, those tariffs could be invalidated and refunds ordered, potentially disrupting fiscal balances and triggering volatility in the dollar and equities.
– If the decision favors the White House, it would cement the executive branch’s ability to impose or adjust tariffs unilaterally, giving the U.S. president far greater flexibility in trade negotiations.

For Bitcoin and the broader crypto market, this legal showdown presents a complex scenario.

Once celebrated for moving independently of traditional markets, Bitcoin now behaves much more like a macro-linked instrument. Over the past several years, Bitcoin’s correlation with the S&P 500 and the Nasdaq Composite has risen sharply, especially during periods of policy-driven volatility.

– If the Supreme Court outcome disrupts confidence in U.S. trade policy or weakens the dollar, risk assets could see renewed speculative inflows, temporarily supporting crypto prices.
– Conversely, a ruling that strengthens executive control and stabilizes the dollar could pressure Bitcoin, as investors move back toward traditional safe assets.

—

### Analyst Outlook and Bitcoin’s Next Move

Market sentiment remains divided on where Bitcoin heads next.

Analyst Ted Pillows noted that Bitcoin has now tested its $107,500 support level for the third or fourth time in just two weeks — a pattern often seen before a decisive breakout or breakdown. He warned that failure to hold this range could open the door for a retest of $100,000, which has served as Bitcoin’s psychological and technical base for much of 2025.

The repeated tests suggest buying strength around $107,000 is weakening, while short-term volatility could rise sharply if that level gives way.

On a more macro level, analyst PlanB, known for the stock-to-flow model, highlighted that Bitcoin closed October at $109,000, marking six straight months above $100,000. He views this range as solidifying long-term support rather than forming a short-term ceiling.

According to his model:

– Bitcoin’s realized price currently sits near $56,000.
– The 55-day moving average is roughly $55,000.

PlanB believes these levels form a structural floor reminiscent of early bull markets in 2013, 2017, and 2021. He also noted that Bitcoin’s Relative Strength Index (RSI) stands at 66, signaling a strong uptrend but not yet in the overheated zone that has historically preceded market tops.

Based on his stock-to-flow projections, Bitcoin’s fair value range lies between $250,000 and $1 million, though he acknowledged wide uncertainty around timing and peaks.

—

### Conclusion

The bullish camp believes the absence of FOMO (Fear of Missing Out) and the steady divergence between realized price and moving average point toward another expansion phase. Meanwhile, the bearish view argues Bitcoin may have already peaked at $126,000 following the halving cycle.

Overall, Bitcoin’s near-term direction depends heavily on whether the $107,000 to $108,000 zone holds. A breakdown below could trigger a sharper correction, while stability above that level could set up the next leg higher.

For now, markets remain heated. Proceed with caution and never invest more than you can afford to lose.
https://bitcoinethereumnews.com/bitcoin/is-the-bitcoin-price-heading-for-its-worst-q4-since-2022/?utm_source=rss&utm_medium=rss&utm_campaign=is-the-bitcoin-price-heading-for-its-worst-q4-since-2022

When Government Competes, America Loses

Posted on by
Reply

In recent years, it has become an unfortunate bipartisan article of faith that the government — and not individuals, nor the businesses or institutions of civil society into which those individuals voluntarily assemble themselves — ought to operate to accomplish any good dreamt up by politicians and the pundit class.

But this fatal conceit, which seeks to subvert the competitive processes of the market and subordinate the will of the free American citizen to the bureaucrat’s, fails not only theoretically but empirically, because state action cannot compete with human action.

To document this, the Taxpayers Protection Alliance has inaugurated a series of policy briefs, chronicling the manifest and myriad failures of central planning and government-run economic endeavors. But first, in the words of Abraham Lincoln, it ought to be understood “where we are, and whither we are tending.”

The movement of Sen. Bernie Sanders (I-Vt.) values ubiquitous and affordable medicine; so, its followers say, government ought to socialize the healthcare industry. Even so-called Abundance Democrats, in revolt against the stultifying excesses of the far left, betray a narrow view that associates economic development too closely with the deeds of the government, albeit a government freed of the worst strictures of such laws as the National Environmental Protection Act.

Republicans, too, have begun to echo the socialist senator from Vermont. Encapsulating this thinking, Treasury Secretary Scott Bessent put it thus: “We believe home ownership is good, so therefore the government wants to be involved.” Proficiency in this language — that of progressives and socialists — has been gained by purported conservatives, who seem to have forgotten their mother tongue.

Indeed, although hardly a radical in temperament, Bessent makes explicit the radical premise from which many Republicans and nearly every Democrat now reason: I approve of X; the government must ensure that X occurs, perhaps even by effecting X directly.

Journeying from its source in principle to its destination in a policy proposal, any idea is refracted, colored, sometimes distorted, as it passes through myriad ideological lenses and filters. And, accordingly, the central planner’s premise, shared by the left and right, takes shape differently in the hands of each, touched by differing philosophical convictions and directed toward different ends.

Joe Biden fretted about carbon emissions and sought to make the composition of energy production, the construction of infrastructure, and even the technologies found in the cars Americans drive and the appliances in American homes a question to be decided by politicians and bureaucrats in Washington, D.C.—efforts which concluded in failure.

President Trump desires more domestic manufacturing; ergo, protectionism. He desires more high-tech, cutting-edge domestic manufacturing; ergo, the federal government acquired a 10-percent stake in Intel, becoming the company’s largest shareholder. He has been persuaded that organized labor is his friend; ergo, he conjured up a “golden share” in U.S. Steel, in no small part to enable his administration to protect the firm’s unionized employees.

In state capitals and city halls, similar assumptions obtain, and similar plans are propounded. For example, in the effort to make access to broadband internet ubiquitous, government-owned networks—which almost invariably founder—have been constructed in cities nationwide. Penetrating the national news cycle, Zohran Mamdani (New York City’s mayor-presumptive) advocated city-run grocery stores, opening their doors in competition with the private sector. No matter that such proposals have, in practice, proved themselves quixotic.

The ideologies of central planning rarely succeed even by the metrics of the planners themselves. So long as people remain people—both in their shortcomings as technocrats and in their independence and interest as entrepreneurs and workers—socialism and its softer, nicer, more palatable progeny will remain a scheme practicable only in Utopia, the land that never was and cannot be.

If men had the psychology and habits of the white ant, perhaps, things would be different; but, as Winston Churchill noted, “human nature is more intractable than ant-nature.” To their chagrin, politicians are left to contend with the world as it is, and with people as they are.

Russell Kirk once wrote: “Ignore the fact, and that fact will be your master.” Trumpian protectionism, single-payer medicine, or Mamdani’s petty socialism—none will succeed. No matter how powerful the force of the will or of the passions that propel them to completion, these projects cannot and, therefore, will not overcome the laws of economics, founded in human nature.

Finding failure, the central planners will run to and fro, searching vainly for some new policy remedy with which to save the patient, ignorant of the fact that the disease was, in the first place, brought on by an unnatural and imprudent course of treatment.

In the words of a popular online meme: “Reject modernity; embrace tradition.” Indeed, both left and right ought to reject the modern innovation of economies directed and micromanaged by the state and return to America’s heritage: liberty, property rights inviolable, and free markets.

—

**Related Articles:**

– Why Free Speech Needs Congressional Action
– Republicans Should Reject European-Style Tech Policy
https://spectator.org/when-government-competes-america-loses/

Tesla Is Still Fighting For Elon Musk’s $56 Billion Payday

Posted on by
Reply

Happy Thursday! It’s October 13, 2025, and welcome to *The Morning Shift*, your daily roundup of the top automotive headlines from around the world—all in one place. Here, you’ll find the most important stories shaping the way Americans drive and get around.

In this morning’s edition, we’re looking at Tesla’s ongoing efforts to pay Elon Musk a massive compensation package, Canada’s displeasure with Stellantis over plans to move Jeep production to the United States, threats to federal funding for General Motors and Stellantis, and yet another Ford recall.

—

### Tesla’s $56 Billion Pay Package Battle Continues

Remember when Elon Musk’s $56 billion pay package was approved, then rescinded, then reinstated, and then rescinded again? Well, Tesla isn’t ready to give up just yet.

According to Reuters, a Tesla attorney argued before the Delaware Supreme Court on Wednesday that Musk’s pay package should have been restored by a shareholder vote last year. This legal battle is entering its final stage after a lower court judge invalidated the CEO’s record-breaking compensation in January 2024.

Tesla is also appealing the court’s rejection of the shareholder vote to reinstate Musk’s pay. This case highlights a familiar dynamic in corporate America: while companies try to pay workers as little as possible, executives often secure enormous compensation packages justified by the need to attract “top talent.”

Of course, executives themselves often set their own pay rates—and that talent attraction rarely trickles down to other roles.

—

### Canada Threatens Legal Action Over Stellantis Jeep Production Shift

Stellantis manufactures many vehicles in Canada, but after tariffs imposed during the Trump administration, the company has started considering shifting some production to the U.S. Unsurprisingly, Canada isn’t happy.

*Automotive News* reports that Canada has threatened legal action following Stellantis’ announcement to move Jeep Compass SUV manufacturing from Brampton, Ontario, to Belvidere, Illinois.

Canada’s Industry Minister Melanie Joly labeled the move “unacceptable,” pointing out that Stellantis had previously received federal and provincial support based on an agreement to maintain its full Canadian footprint, including the Brampton plant.

Joly demanded Stellantis quickly identify new production mandates for the Brampton facility to keep it central to the company’s manufacturing footprint and ensure contracts with Canadian suppliers are honored.

While Canada may care less about the Compass specifically, the government is adamant that the Brampton factory continues operating. If it switches to making something else, that’s fine, but it has to stay active.

—

### Federal Funding at Risk for GM and Stellantis Amid Political Shifts

Since the Trump administration prioritized rolling back climate-focused programs, the future of federal funding for progressive initiatives has become uncertain. These programs, often dismissed as “leftist” or “socialist,” include projects supporting electric vehicles and green technology.

*Automotive News* shares that the Department of Energy recently terminated funding for 233 projects described as part of “the Left’s climate agenda.” Included in a leak published by news outlet Semafor on October 7 are several awards tied to automotive giants: five for General Motors, two for Stellantis, plus others involving Bosch and Plug Power.

While the list has not been officially confirmed, Semafor has a reliable track record.

If GM and Stellantis begin losing federal funding—especially given that the U.S. has pushed them to conduct business domestically, sometimes at the expense of international advantages—their financial outlook and strategic calculations could change drastically.

—

Stay tuned for more updates throughout the day!
https://www.jalopnik.com/1998560/tesla-still-fighting-for-elon-musk-56-billion-dollar-package/

Dutch government seizes control of China-owned chipmaker amid trade tensions

Posted on by
Reply

**Dutch Government Seizes Control of China-Owned Chipmaker Amid Trade Tensions**

*By Mudit Dube | Oct 13, 2025, 04:09 PM*

—

The Dutch government has taken control of Nexperia, a Chinese-owned semiconductor manufacturer, amid escalating global trade tensions and growing national security concerns. Nexperia is a key supplier of chips to the European automotive and consumer electronics sectors.

The intervention was officially announced by the Dutch Minister of Economic Affairs on Sunday, marking a significant move in the ongoing scrutiny of foreign ownership in critical technology industries.

### Security Concerns Prompt Government Action

Invoking the “Goods Availability Act,” the Dutch government placed Nexperia under external management to prevent potential disruptions in the supply of vital goods during emergencies. This decision comes amid heightened trade tensions between the United States and China and follows Beijing’s recent tightening of rare earth element export restrictions—materials essential to European manufacturing.

### Governance Issues at Nexperia

The Dutch authorities cited “recent and acute signals of serious governance shortcomings and actions” within Nexperia as a key reason for their intervention. These deficiencies reportedly threaten the continuity and protection of crucial technological expertise and capabilities within both the Netherlands and Europe.

This move reflects increased government vigilance over Chinese-owned entities operating in sensitive sectors such as semiconductor manufacturing.

### Market Impact

Following the announcement, Wingtech Technology Co., the Chinese parent company that acquired Nexperia for $3.6 billion in 2019, saw its shares fall by the daily limit of 10%.

Despite the government’s intervention, Nexperia is allowed to continue its regular production. However, the Dutch government now holds the authority to block or reverse company decisions. Additionally, Wingtech has been ordered to suspend any changes to Nexperia’s assets, business operations, or personnel for up to one year.

### Wingtech Responds to Government Measures

Wingtech has condemned the Dutch government’s action, describing it as an “excessive intervention driven by geopolitical bias, rather than a fact-based risk assessment.” The company maintains that it has “strictly abided by the laws and regulations of all jurisdictions” and operates with transparency at its sites in the Netherlands, Germany, and the United Kingdom.

—

The Dutch government’s seizure of Nexperia highlights the increasing tensions and complexities surrounding foreign investments in strategic industries amid shifting global power dynamics.
https://www.newsbytesapp.com/news/business/dutch-government-takes-control-of-chinese-owned-semiconductor-manufacturer-nexperia/story

Cough syrup deaths: PIL in SC seeks CBI probe

Posted on by
Reply

**Cough Syrup Deaths: PIL in Supreme Court Seeks CBI Probe**

*By Snehil Singh | October 7, 2025, 4:29 PM*

A Public Interest Litigation (PIL) has been filed in the Supreme Court seeking a Central Bureau of Investigation (CBI) probe into the deaths of 14 children in Madhya Pradesh, allegedly after consuming a cough syrup. The PIL demands an investigation led by a retired Supreme Court judge into the manufacturing, regulation, testing, and distribution of contaminated cough syrups, ANI reported.

Several children across different states reportedly died after consuming Coldrif cough syrup, which was found to contain diethylene glycol (DEG), a highly toxic industrial solvent.

### Ban and Quality Concerns

The Union Health Ministry has confirmed that Coldrif cough syrup, produced by Sresan Pharma in Tamil Nadu, contained DEG levels beyond permissible limits. A Drug Testing Laboratory in Chennai declared the product “Not of Standard Quality” after testing a sample, a finding also confirmed by the Tamil Nadu Directorate of Drug Control.

Following these findings and mounting concerns due to child deaths linked to suspected renal failure, Tamil Nadu became the first state to ban the sale and distribution of Coldrif syrup.

### Actions Taken by Other States

In response to the crisis, Madhya Pradesh and Kerala have also banned Coldrif cough syrup. Telangana issued a public alert warning consumers about the product, while the Punjab government directed all retailers and healthcare institutions to cease purchasing or using Coldrif.

The tragic incident has led to widespread confiscation of stock nationwide and prompted stringent revisions to drug prescription guidelines in states such as Kerala and Karnataka.

### Historical Context: WHO Warnings Over Indian Cough Syrups

This is not the first time Indian-made cough syrups have been linked to fatal outcomes. In 2022, the World Health Organization (WHO) associated cough syrups from Maiden Pharmaceuticals with the deaths of 70 children in The Gambia due to acute kidney injuries caused by DEG and ethylene glycol (EG).

In 2023, Uzbekistan reported at least 18 child deaths linked to Indian-made cough syrup manufactured by Marion Biotech, triggering another WHO warning.

—

The ongoing investigation and regulatory actions highlight the urgent need for stricter quality control and oversight in pharmaceutical manufacturing to prevent such tragic incidents in the future.
https://www.newsbytesapp.com/news/india/cough-syrup-deaths-pil-seeks-cbi-probe-states-ban-coldrif/story

11 children’s deaths: Drug watchdog urges strict action against Coldrif

Posted on by
Reply

**11 Children’s Deaths: Drug Watchdog Urges Strict Action Against Coldrif**

*By Snehil Singh | Oct 05, 2025, 11:11 am*

The Central Drugs Standard Control Organisation (CDSCO) is gearing up to take stringent action against the manufacturers of Coldrif syrup following the tragic deaths of 11 children, allegedly due to contaminated cough syrups.

The CDSCO has directed the Tamil Nadu Food and Drug Administration (FDA) to initiate strict measures under serious offense regulations, according to a report by news agency ANI.

### National Conference and Government Response

In response to this crisis, the Union Health Secretary is set to hold a video conference with health officials from all states and Union Territories. The meeting’s objective is to discuss the rational use of cough syrups and enforce drug quality standards nationwide.

This step comes after the deaths of 11 children in Madhya Pradesh and Rajasthan were linked to the consumption of contaminated cough syrups, raising serious concerns about drug safety.

### Ongoing Investigation and Risk-Based Inspections

The CDSCO has launched risk-based inspections of drug manufacturing units across six states — Himachal Pradesh, Uttarakhand, Gujarat, Tamil Nadu, Madhya Pradesh, and Maharashtra. Investigators have collected 19 samples from these states for thorough testing.

A multidisciplinary team of experts is currently analyzing the samples to pinpoint the exact cause behind the deaths reported in Chhindwara, Madhya Pradesh.

### Sample Analysis and Findings

Earlier this week, the CDSCO confirmed that six samples tested by them, along with three from the Madhya Pradesh Food and Drugs Administration, were free from toxic compounds such as Diethylene Glycol (DEG) and Ethylene Glycol (EG). These substances are known to cause severe kidney damage.

However, it was clarified that the tested samples did not include the two suspicious cough syrups, including Coldrif, which remain under scrutiny.

### Regional Actions Against Coldrif Syrup

In light of these developments, several states have taken proactive measures against Coldrif syrup. Kerala, Tamil Nadu, and Madhya Pradesh have imposed bans on its sale. Telangana has issued a public alert urging people to stop using the product immediately.

These actions are part of broader efforts to ensure drug safety and uphold quality standards across India, following the heartbreaking loss of children linked to contaminated cough syrups.

The investigation is ongoing, and authorities continue to monitor the situation closely to prevent further casualties.
https://www.newsbytesapp.com/news/india/drug-watchdog-urges-strict-action-against-coldrif-makers-report/story

11 children’s deaths: Drug watchdog urges strict action against Coldrif

Posted on by
Reply

**11 Children’s Deaths: Drug Watchdog Urges Strict Action Against Coldrif**

*By Snehil Singh | Oct 05, 2025, 11:11 AM*

The Central Drugs Standard Control Organisation (CDSCO) is set to take stringent action against the manufacturers of Coldrif syrup following the tragic deaths of 11 children, allegedly caused by contaminated cough syrups.

According to reports from ANI, the CDSCO has directed the Tamil Nadu Food and Drug Administration (FDA) to initiate strict measures under serious offense provisions to tackle this grave issue.

—

**Union Health Secretary to Convene National Conference**

In response to the crisis, the Union Health Secretary will conduct a video conference with health officials from all states and Union Territories. The discussion will focus on the rational use of cough syrups and enforcing drug quality standards nationwide.

This move follows the deaths of 11 children in Madhya Pradesh and Rajasthan, which have been linked to contaminated cough syrups.

—

**Ongoing Investigations and Inspections**

The CDSCO has launched risk-based inspections targeting drug manufacturing units across six states: Himachal Pradesh, Uttarakhand, Gujarat, Tamil Nadu, Madhya Pradesh, and Maharashtra.

Authorities have collected 19 samples from these regions for comprehensive testing. A multidisciplinary team of experts is currently analyzing the samples to uncover the cause behind the fatalities in Chhindwara, Madhya Pradesh.

—

**Sample Analysis Results**

Earlier this week, the CDSCO confirmed that six of its tested samples, along with three from the Madhya Pradesh Food and Drugs Administration, were free from toxic compounds such as Diethylene Glycol (DEG) and Ethylene Glycol (EG). These chemicals are notorious for causing severe kidney damage.

However, officials clarified that these tested samples did not include the two cough syrups under suspicion, including Coldrif.

—

**Regional Actions Against Coldrif Syrup**

In light of the findings, several states have taken immediate action against Coldrif syrup. Kerala, Tamil Nadu, and Madhya Pradesh have imposed bans on its sale. Meanwhile, Telangana has issued a public alert advising citizens to discontinue use of the product.

These measures are part of a larger effort to ensure drug safety and quality across India, following the heartbreaking loss of young lives allegedly linked to contaminated cough syrups.

—

*Stay tuned for further updates on this developing story.*
https://www.newsbytesapp.com/news/india/drug-watchdog-urges-strict-action-against-coldrif-makers-report/story

11 children’s deaths: Drug watchdog urges strict action against Coldrif

Posted on by
Reply

**11 Children’s Deaths: Drug Watchdog Urges Strict Action Against Coldrif**

*By Snehil Singh | Oct 05, 2025, 11:11 AM*

—

The Central Drugs Standard Control Organisation (CDSCO) is set to take stringent action against the manufacturers of Coldrif syrup following the tragic deaths of 11 children, allegedly caused by contaminated cough syrups.

According to reports from ANI, the CDSCO has directed the Tamil Nadu Food and Drug Administration (FDA) to initiate strict measures under serious offenses to address the issue.

**National Conference to Address Drug Safety**

In response to the incident, the Union Health Secretary will conduct a video conference with health officials from all states and Union Territories. The meeting aims to discuss the rational use of cough syrups and enhance drug quality standards across India.

This initiative comes amid investigations linking the deaths of 11 children in Madhya Pradesh and Rajasthan to contaminated cough syrups.

**Ongoing Investigation and Risk-Based Inspections**

The CDSCO has commenced risk-based inspections of drug manufacturing units in six states: Himachal Pradesh, Uttarakhand, Gujarat, Tamil Nadu, Madhya Pradesh, and Maharashtra.

Authorities have collected 19 samples from these regions for comprehensive testing. A multidisciplinary team of experts is currently analyzing these samples to determine the cause of fatalities in Chhindwara, Madhya Pradesh.

**Sample Analysis Results**

Earlier this week, the CDSCO confirmed that six tested samples, along with three from the Madhya Pradesh Food and Drugs Administration, were free from toxic compounds such as Diethylene Glycol (DEG) and Ethylene Glycol (EG). These substances are known to cause severe kidney damage.

However, officials noted that these tested samples did not include the two cough syrups currently under scrutiny, including Coldrif.

**Regional Actions Taken**

Following the CDSCO’s findings, several states have taken decisive steps against Coldrif syrup. Kerala, Tamil Nadu, and Madhya Pradesh have banned the sale of the product.

Meanwhile, Telangana has issued a public alert advising people to stop using Coldrif syrup immediately.

These actions form part of a broader effort to safeguard drug safety and quality in India after the unfortunate deaths linked to contaminated cough syrups.

—

*Stay tuned for updates on this developing story.*
https://www.newsbytesapp.com/news/india/drug-watchdog-urges-strict-action-against-coldrif-makers-report/story